Global Cell Surface Markers Detection Market - 2021-2028
|出版日期||內容資訊||英文 180 Pages
|全球細胞表面標記檢測市場:2021∼2028年 Global Cell Surface Markers Detection Market - 2021-2028|
|出版日期: 2021年08月20日||內容資訊: 英文 180 Pages||
表面及細胞內的蛋白質，是為了識別特定的種類的細胞，掌握細胞族群特徵的重要標記。Cellometer Vision CBA圖像細胞儀，為了揭示細胞族群的特徵，專為表面標誌物和細胞內蛋白質的螢光分析而設計。對精密醫療的需求高漲和診斷技術的提高，將帶動細胞表面標記檢測市場。
Cell Surface Markers Detection Market Overview
The cell surface markers detection market size was valued at US$ YY billion in 2020 and is estimated to reach US$ YY billion by 2028, growing at a CAGR of YY % during the forecast period (2021-2028).
Surface and intracellular proteins are important markers for identifying specific types of cells and characterizing cell populations. The Cellometer Vision CBA image cytometer is specifically designed to perform surface marker and intracellular protein fluorescence analysis to characterize cell populations.
Cell Surface Markers Detection Market Dynamics
Increasing demand for precision medicine and increased diagnostics is estimated to drive the cell surface markers detection market.
Increasing demand for precision medicine is estimated to drive the cell surface markers detection market
According to the precision medicine initiative, it is an emerging approach for disease treatment and prevention that considers individual variability in genes, environment, and lifestyle for each person. Although it is relatively new, the concept has been a part of healthcare for many years. For example, a person who needs a blood transfusion is not given blood from a randomly selected donor instead, the donor's blood type is matched to the recipient to reduce the risk of complications.
Personalized medicine requires developing a wide array of biomarker diagnostic assays, reflecting individual variations and thus allowing tailored therapeutic interventions. Membrane proteins comprise approximately 30% of human proteins, they play a key role in various physiological functions and pathological conditions. Currently, only a limited number of membrane proteins are applied as biomarkers. Cell surface membrane proteins are not easily accessible for diagnostic sampling in many normal tissues and tumor-derived membrane preparations while serving as potential tumor biomarkers may not reflect physiological protein expression. However, cell surface membrane proteins already serve as valuable prognostic and predictive biomarkers, for example, in hematological and immunological diseases, by determining the cluster of differentiation markers.
Increased use of diagnostics is estimated to drive the cell surface markers detection market in the forecast period
The human body is a complex environment made up of different types of cells interacting with one another and their environment. To best understand the numerous interactions, cells need to be differentiated from one another recognizably. The way we can distinguish cell types from one another is by using cell surface markers. Proteins and carbohydrates attached to the cellular membrane are cell surface markers, allowing them to play an integral role in intercellular signaling. Using the cell surface markers makeup present on a given cell, we can identify and distinguish it from the surrounding cells population. Common cell surface markers such as CD3, CD8, CD4 and CD25 are used commonly to identify T cells into their cytotoxic, helper and regulatory T cells subcategories. Being able to determine the quantity and presence of certain types of cells in a sample can influence decisions regarding clinical trial enrollment, drug development, diagnosis and much more. To determine the cell surface markers there are multiple methods available within a population present on cells. These methods include Immunohistochemistry, Flow Cytometry and Next Generation Sequencing.
The qualitative rapid assessment of surface markers on cancer cells allows point-of-care prediction of patient response to various cancer drugs. Preclinical studies are targeting cells with an antibody to "activated" matriptase conjugated to a potent toxin showing promise as a selective treatment for various solid tumors. A novel technique for the electrical detection of proteins on surfaces of cancer cells using multi-frequency microfluidic impedance cytometry was detected. The gold standard technology for cancer cell isolation and marker assessment is the CellSearch CTC (Circulating Tumor Cells) Test, which uses magnetic bead-based pre-concentration and fluorescent tagging fluorescently analyzing the cell surfaces.
Drawbacks in the cell surface markers detection technique are estimated to hamper the market
Practically, it has proven difficult to discern stem and progenitor cells with therapeutic potential from other cells within vitro differentiation potential, including some that may have undergone transformation or epigenetic modifications. In the most conservative case, stem cells need to be defined as single cells that are clonal precursors of more stem cells of the same type and differentiated progeny. Accordingly, only when stem or progenitor cells have been purified to homogeneity as a primary isolate can one know with certainty that the generation of expected (or unexpected) progeny is a property of a known cell type, barring culturing issues course. Based on these stringent criteria, only rarely have stem cells been identified as clonogenic precursors (e.g., long-term repopulating HSC) that include both self-renewed stem cells and differentiated progeny in their progeny.
To date, no single marker has thus far proved sufficient to unambiguously define an authentic stem cell or a unique stem-cell function. The goal, therefore, is to ultimately correlate the function of a pure population of stem cells with a panel of defined cell-surface protein markers. Thus, when the functional assays have been adequately tested, the use of a well-defined panel of markers for positive and negative selection can be employed to identify authentic stem cell populations that have therapeutic potential. This concept proved highly effective in primary bone marrow-derived HSC, which are composed of long-term and short-term repopulating cells and myeloid and lymphoid progenitors. Importantly, only the long-term repopulating HSC, which display a unique set of markers (Murine: cKit+, Sca1+, Lin-; Human: CD34+Thy-1+Lin-), correspond to the authentic HSC that are suitable for long-term replacement therapy. Regrettably, very few other stem cells have been adequately defined by markers for therapeutic interventions due to the challenges in identifying new potential protein markers.
COVID-19 Impact Analysis
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience negative health and occupational effects from the COVID-19 pandemic. This has been seen to positively affect the cell surface markers detection market as many research projects are being carried out which involve the interaction of COVID-19 antibodies with cell surface markers.
Cell Surface Markers Detection Market Segment Analysis
The flow Cytometry segment is expected to dominate the cell surface markers detection market
Flow Cytometry is a technique used to detect and measure the physical and chemical characteristics of a population of cells or particles. In this process, a sample containing cells or particles is suspended in a fluid and injected into the flow cytometer instrument. Flow cytometry is a powerful tool with applications in multiple disciplines such as immunology, virology, molecular biology, cancer biology and infectious disease monitoring. For example, it is very effective for studying the immune system and its response to cancer and infectious diseases. It allows the simultaneous characterization of mixed populations of cells from blood,bone marrow and solid tissues that can be dissociated into single cells such as lymph nodes, spleen, mucosal tissues, solid tumors etc. In addition to analysis of populations of cells, a major application of flow cytometry is sorting cells for further analysis. Flow cytometry has a wealth of techniques and applications that are suitable for multiple fields of study. The most used application in flow cytometry is immunophenotyping. It utilizes the unique ability of flow cytometry to analyze mixed populations of cells for multiple parameters simultaneously.
An immunophenotyping experiment in its simplest form consists of cells stained with fluorochrome-conjugated antibodies targeted against antigens on the cell surface. Most of these antigens are given "cluster of differentiation" numbers or CD numbers by the Human Leukocyte Differentiation Workshops. A common nomenclature is used to define monoclonal antibodies directed against specific cellular antigens. For example, CD3 is a "cluster of differentiation number 3" and is used to define the T cell co-receptor present on all T cells. Most immune cells have specific CD markers that define them as a population of cells. These cell markers are called lineage markers and are used to define specific cell populations for additional analysis in each immunophenotyping experiment. Examples are the T cell markers (CD3, CD4, CD8), B cell markers (CD19, CD20), monocyte markers (CD14, CD11b) and NK cell markers (CD56, CD161). In addition to lineage markers that define populations of cells, other markers are used to characterize each cell population. These markers can include activation markers (CD69, CD25, CD62L), memory markers (CD45RO, CD27), tissue homing markers (α4/B7) and chemokine receptor markers (CCR7, CCR5, CXCR4, CCR6).Often, immunophenotyping experiments also include intracellular markers such as FoxP3 (defines Treg cells), cytokines (IFN-γ, TNF-α, IL-2 define TH1 cells), proliferation markers (Ki67, CFSE), and antigen-specific markers (major histocompatibility or MHC Tetramers). Evaluation for the presence or absence of multiple cell-surface markers by using polychromatic flow cytometry constitutes the basis of clinical immunophenotyping. This allows for the characterization of cell populations and subpopulations, identification of the status of cell differentiation, and quantification of surface proteins associated with specific cellular functions. By using flow cytometry, the determination of immunophenotypic characteristics of T, B, and natural killer (NK) cell subsets allows classification of patients with severe combined immunodeficiency (SCID) into different categories that have historically narrowed the search for possible underlying genetic defects.
The disease Diagnosis and Identification segment is estimated to dominate the cell surface markers detection market
An innovative global health discussion platform allows the global health community to capture insights on factors driving demand and supply for diagnostics. Biomarkers are biomolecules that serve as indicators of pathological and biological processes or physiological and pharmacological responses to drug treatment. Due to the high abundance of albumin and heterogeneity of plasma lipoproteins and glycoproteins, biomarkers are difficult to identify in human serum. Due to the clinical significance, identifying disease biomarkers in serum holds great promise for personalized medicine, especially for disease diagnosis and prognosis.
The practical application of identification technique or each protein separation is analyzed by specific examples. Biomarkers of cancers of prostate, ovary, breast, and lung in human serum have been reviewed, as well as those of heart disease, arthritis, asthma, and cystic fibrosis. However, the Food and Drug Administration approved the advancement of technology for disease diagnosis and prognosis due to the complexity of structure and function of protein biomarkers and lack of high sensitivity, specificity, and reproducibility for those putative biomarkers. Combining different types of technologies and statistical analysis may provide more effective methods to identify and validate new disease biomarkers in blood. Hence, due to the demand for disease identification and diagnosis markers, this segment is assumed to dominate the market.
Cell Surface Markers Detection Market Geographical Analysis
North America region is estimated to dominate the cell surface markers detection market
With rapidly growing applications in disease diagnostics, well-established research institutes and major key players are estimated to drive the market in this region.
In the United States prostate cancer is the third most common form of cancer. In 2021, The American Cancer Society estimates that in American men prostate cancer will be the most commonly diagnosed cancer with 248,530 new cases predicted. To image patients with prostate cancer computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, and certain nuclear medicine scans are commonly used.These imaging techniques however have limitations in the detection of prostate cancer lesions. FDA approved the first PSMA-targeted PET imaging drug, Ga 68 PSMA-11, on December 1, 2020, for the same prostate cancer imaging indications as Pylarify. Marketed Ga 68 PSMA-11 is currently only available locally at two sites in California. Pylarify is anticipated to be distributed from multiple sites throughout the United States.
There are 261 research universities in the United States. There are other recognized ways of determining what a research university is and which are of the highest quality.
Cell Surface Markers Detection Market Competitive Landscape
Major key players in the cell surface markers detection market are Becton, Dickinson and Company, Nihon Kohden Corporation, Luminex Corporation, Sysmex Corporation and Thermo Fisher Scientific, Inc., McKesson Corporation, Cerner Corporation, Swisslog (KUKA), Yuyama, Capsa Healthcare, Guangzhou Medunion Technologies Co.ltd, Merit Medical Systems, Inc. and Guangzhou Maya Medical Equipment.Co.ltd
Cell Surface Markers Detection Market Key Companies to Watch
Becton, Dickinson and Company
Overview: Globally, one of the largest global medical technology companies BD is advancing the world of health by improving diagnostics, medical discovery and the delivery of care. The company supports the frontline heroes of health care by developing innovative technology, solutions and services that help advance clinical therapy for patients and clinical processes for health care providers.The company and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians care delivery process, enable laboratory scientists to diagnose disease and advance researchers' capabilities better to develop the next generation of therapeutics and diagnostics. Worldwide, BD has a presence in virtually every country and partners with organizations to address some of the most challenging global health issues. By working in close collaboration with customers,the company can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
Product Portfolio: The company comprises Medical Devices, Biosciences, Medical Supplies, Laboratory Instruments, Reagents, Diagnostics Products, Antibodies, Surgical and Vascular Access.
Key Development: BD (Becton, Dickinson and Company), a leading global medical technology company, announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alari System, the most widely used infusion pump in acute care hospitals across the United States.
The cell surface markers detection market report would provide an access to an approx. 53 market data table, 43 figures and 180 pages.
Cell Surface Markers Detection Market - By Product
Cell Surface Markers Detection Market - By Application
Cell Surface Markers Detection Market - By Region
LIST NOT EXHAUSTIVE